Mereo Biopharma Group PLC (MREO) — SEC Filings
Mereo Biopharma Group PLC (MREO) — 37 SEC filings. Latest: ARS (Apr 9, 2026). Includes 14 8-K, 8 SC 13G/A, 6 10-Q.
View Mereo Biopharma Group PLC on SEC EDGAR
Overview
Mereo Biopharma Group PLC (MREO) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a ARS filed on Apr 9, 2026: Mereo BioPharma Group plc filed an Annual Report to Security Holders (ARS) on April 9, 2026, for the period ending December 31, 2025. The company, headquartered in London, United Kingdom, is involved in the pharmaceutical preparations industry.
Sentiment Summary
Across 37 filings, the sentiment breakdown is: 2 bullish, 1 bearish, 32 neutral, 2 mixed. The dominant filing sentiment for Mereo Biopharma Group PLC is neutral.
Filing Type Overview
Mereo Biopharma Group PLC (MREO) has filed 1 ARS, 14 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 8 SC 13G/A, 2 SC 13G, 2 SC 13D/A with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (37)
Risk Profile
Risk Assessment: Of MREO's 23 recent filings, 2 were flagged as high-risk, 11 as medium-risk, and 10 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $500,000 |
| Net Income | -$34,527,000 |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $48,698,000 |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Mereo Two Thousand And Nineteen Equity Incentive Plan
- Two Thousand And Nineteen Non-Executive Director Equity Incentive Plan
- Brian Kleinhaus
Industry Context
Mereo BioPharma operates in the highly competitive and capital-intensive biopharmaceutical industry. The sector is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Success hinges on the ability to bring novel therapies through clinical trials and gain regulatory approval, often facing competition from established pharmaceutical giants and other biotech firms.
Top Tags
biopharma (5) · 10-Q (4) · 8-K (4) · sec-filing (3) · financials (3) · financial-reporting (3) · Mereo BioPharma (3) · annual-report (2) · Biopharma (2) · Net Loss (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| ARS PDF Size | 760465 | Size of the Annual Report to Security Holders PDF document. |
| Text File Size | 1048943 | Size of the complete submission text file. |
| Cash and cash equivalents | $48.7M | Decreased from $69.8M at Dec 31, 2024, to $48.7M at Sep 30, 2025 |
| Net loss (Q3 2025) | $7.024M | Improved from $15.001M net loss in Q3 2024 |
| Net loss (YTD Sep 2025) | $34.527M | Improved from $36.207M net loss in YTD Sep 2024 |
| Revenue (YTD Sep 2025) | $500K | Increased from $0 in YTD Sep 2024, primarily from out-licensing |
| Research and development expenses (YTD Sep 2025) | $13.573M | Increased from $12.109M in YTD Sep 2024 |
| Accumulated deficit | $493.7M | As of September 30, 2025, indicating historical losses |
| Ordinary shares outstanding | 795,658,504 | As of November 7, 2025 |
| Cash runway | 12 months | Expected to fund operations for at least 12 months from filing date |
| Net Loss | $10.2M | Net loss for the three months ended June 30, 2025, an improvement from $15.8M in the prior year. |
| Period End Date | 2025-06-30 | The reporting period for this 10-Q filing. |
| AstraZeneca Agreement Start | 2017-10-01 | Date of the license agreement with AstraZeneca. |
| Novartis Loan Note Date | 2020-02-10 | Date of the Novartis loan note. |
| Repronovo Partnership Start | 2025-04-01 | Start date of the collaboration and licensing agreement with Repronovo Partnership. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Mereo Biopharma Group PLC (MREO)?
Mereo Biopharma Group PLC has 37 recent SEC filings from Jan 2024 to Apr 2026, including 14 8-K, 8 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of MREO filings?
Across 37 filings, the sentiment breakdown is: 2 bullish, 1 bearish, 32 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Mereo Biopharma Group PLC SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Mereo Biopharma Group PLC (MREO) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Mereo Biopharma Group PLC?
Key financial highlights from Mereo Biopharma Group PLC's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for MREO?
The investment thesis for MREO includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Mereo Biopharma Group PLC?
Key executives identified across Mereo Biopharma Group PLC's filings include Mereo Two Thousand And Nineteen Equity Incentive Plan, Two Thousand And Nineteen Non-Executive Director Equity Incentive Plan, Brian Kleinhaus.
What are the main risk factors for Mereo Biopharma Group PLC stock?
Of MREO's 23 assessed filings, 2 were flagged high-risk, 11 medium-risk, and 10 low-risk.
What are recent predictions and forward guidance from Mereo Biopharma Group PLC?
Forward guidance and predictions for Mereo Biopharma Group PLC are extracted from SEC filings as they are enriched.